Compare Agilent Technologies Inc (A) vs Expensify Inc (EXFY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilent Technologies Inc vs Expensify Inc — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while Expensify Inc trades at $2.27 (market cap $224.32M). The key difference: Agilent Technologies Inc is far larger — about 187.2× Expensify Inc's market cap, and Agilent Technologies Inc pays a 0.69% dividend while Expensify Inc pays none. Which is the better fit depends on your goals.
| A | EXFY | |
|---|---|---|
Market Cap | $42.00B | $224.32M |
Sector | Health | Technology |
52-Week High | $157.20 | $2.69 |
52-Week Low | $110.24 | $0.75 |
Enterprise Value | $43.55B | $163.94M |
Dividend Yield | 0.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
Expensify (EXFY) trades at $2.69, up 35.86% in 24 hours, with a bullish technical signal from moving averages but overbought RSI levels. The company reported Q2 2026 revenue of $33.9 million, beating EPS estimates, and raised free cash flow guidance. Despite negative net margins, cash flow from operations improved to $20.09 million in 2025, and the balance sheet shows $48.77 million in cash with low debt.
The outlook is cautiously optimistic due to earnings beats and AI-driven growth initiatives, but high P/E of 258.82 and persistent losses pose valuation risks. Analyst consensus is split between Buy and Hold, reflecting uncertainty over profitability sustainability amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →
